C=x Bonded Directly Or Indirectly By An Acyclic Carbon Or Carbon Chain To Ring Carbon Of The Five-membered Hetero Ring (e.g., Tryptophan, Etc.) (x Is Chalcogen) Patents (Class 514/419)
-
Publication number: 20130274261Abstract: Methods of treating pulmonary hypertension are disclosed. Particular methods comprise the administration of a tryptophan hydroxylase inhibitor and a prostacyclin. Pharmaceutical formulations are also disclosed.Type: ApplicationFiled: March 18, 2013Publication date: October 17, 2013Inventor: Arthur T. SANDS
-
Publication number: 20130267493Abstract: The present invention relates to indole and indazole compounds of Formula (I) that activate 5? adenosine monophosphate-activated protein kinase (AMPK). The invention also encompasses pharmaceutical compositions containing these compounds and methods for treating or preventing diseases, conditions, or disorders ameliorated by activation of AMPK.Type: ApplicationFiled: March 15, 2013Publication date: October 10, 2013Applicant: PFIZER INC.Inventors: Samit Bhattacharya, Kimberly Cameron, Matthew Dowling, Dilinie Fernando, David Ebner, Kevin Filipski, Daniel Kung, Esther Lee, Aaron Smith, Meihua Tu
-
Publication number: 20130267469Abstract: Indole-3-propionic acid as a marker and for treatment for Huntington Disease.Type: ApplicationFiled: March 14, 2013Publication date: October 10, 2013Applicant: COUNTERPOINT HEALTH SOLUTIONS, INC.Inventor: Wayne Matson
-
Patent number: 8551529Abstract: The present invention relates to a process for the preparation of a composition for the production of tablets and to a composition obtained thereby. This composition is a directly compressible composition which results both in improved tabletting properties and in improved tablet properties.Type: GrantFiled: July 7, 2010Date of Patent: October 8, 2013Assignee: Merck Patent GmbHInventors: James Easson, Walter Hamm, Guenter Moddelmog
-
Publication number: 20130261130Abstract: The invention relates to acylamino-phthalic acid amides and related compounds of formula (I) wherein A is —CON—R3R4, —NR5COR6, —NHR7, —OR8, —SR9, —CH2NR10R11, —(CH2)2-R12, —CH?CH—R12, —C?C—R12, optionally substituted phenyl, optionally substituted thiophenyl, or optionally substituted 1,2,3-triazol-4-yl, W is hydrogen, hydroxy or carboxymethoxy, Y is carboxy, methoxycarbonyl or 2H-tetrazol-5-yl, and the various substituents R have the meanings indicated in the description. These compounds are useful for the treatment and/or prophylaxis of skeletal muscle atrophy, schizophrenia and Alzheimer's disease, and as cognitive enhancers.Type: ApplicationFiled: October 31, 2011Publication date: October 3, 2013Inventors: Shaheen Ahmed, Stefan Hettwer, Jan Willem Vrijbloed, Carlo Farina, Hans Allgeier
-
Publication number: 20130252989Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.Type: ApplicationFiled: May 17, 2013Publication date: September 26, 2013Applicant: AMARIN PHARMACEUTICALS IRELAND LIMITEDInventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Publication number: 20130251664Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.Type: ApplicationFiled: March 8, 2013Publication date: September 26, 2013Applicant: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.Inventor: Richard T. Lee
-
Publication number: 20130252990Abstract: The present invention relates to, inter alia, pharmaceutical compositions comprising a polyunsaturated fatty acid and to methods of using the same to treat or prevent cardiovascular-related diseases.Type: ApplicationFiled: May 17, 2013Publication date: September 26, 2013Applicant: Amarin Pharmaceuticals Ireland LimitedInventors: Mehar Manku, Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni
-
Publication number: 20130245064Abstract: The invention relates to novel acylamino-hydroxy-benzamides of formula (I), wherein R1 is phenyl substituted by phenyl, phenoxy, phenylamino or heteroaryl, all optionally further substituted; bicyclic aryl, monocyclic heteroaryl substituted by optionally substituted phenyl, or bicyclic heteroaryl, R2 is hydrogen or methyl, and R3 and R4 have the meanings indicated in the description. These compounds are useful for the treatment and/or prophylaxis of skeletal muscle atrophy, schizophrenia and Alzheimer's disease, and as cognitive enhancers.Type: ApplicationFiled: October 31, 2011Publication date: September 19, 2013Inventors: Shaheen Ahmed, Stefan Hettwer, Jan Willem Vrijbloed, Carlo Farina, Piero Paravidino
-
Patent number: 8536216Abstract: Compositions based on amino acids are described, in particular for oral or parenteral use, suitable for treating heart insufficiency. The compositions according to the invention comprise up to 75% of the branched chain amino acids leucine, isoleucine and valine, as active ingredients. Preferably, the compositions also comprise, as further active ingredients, up to 50% of theronine and lysine. Other essential amino acids are preferably also provided (in particular methionine, phenylalanine, histidine, triphtophan) as well as non essential amino acids (in particular tyrosine and/or cyst(e)ine—i.e., cystine and cyst(e)ine). Other amino acids can be added, provided that their sum is in a percentage being lower than 20% with respect to the other active ingredients, and less than 10% for each single amino acid.Type: GrantFiled: January 26, 2011Date of Patent: September 17, 2013Assignee: Professional Dietetics S.R.L.Inventor: Francesco Saverio Dioguardi
-
Publication number: 20130236551Abstract: It is described the use of a combination consisting of a microcapsule suspension comprising one or more statins in alkyl esters of n-3 PUFA in which the statins are isolated from contact with the alkyl ester of n-3 PUFA by means of a polymeric membrane that can be easily disintegrated in the gastrointestinal medium, for the treatment of cardiovascular diseases.Type: ApplicationFiled: November 30, 2010Publication date: September 12, 2013Applicant: DEFIANTE FARMACEUTICA .S.A.Inventors: Anna Atti, Enrico Cavazza, Silvia Cavazza, Francesca Cavazza, Martina Cavazza Preta
-
Publication number: 20130237577Abstract: Composition comprising leucine, isoleucine, valine, threonine and lysine for use in prophylactic and/or therapeutic treatment of renal disorders in a subject, preferably an elderly subject.Type: ApplicationFiled: January 12, 2011Publication date: September 12, 2013Inventors: Francesco Saverio Dioguardi, Edoardo Carlo Maria Conti, Giovanni Federico Maria Conti, Isabella Arborio Mella
-
Publication number: 20130237579Abstract: The present invention relates to stable pharmaceutical compositions comprising one or more HMG-CoA reductase inhibitors, processes for preparing the stable compositions and uses for the compositions. The stable pharmaceutical compositions of the invention may be used, in particular, for the treatment of hyperlipoproteinemia and atherosclerosis.Type: ApplicationFiled: July 11, 2008Publication date: September 12, 2013Inventors: Timothy Stanley, Isabel Delgado, Estela Llorens, Eva Munoz
-
Publication number: 20130236468Abstract: The present invention relates to a combination comprising compounds of formula (I): wherein R1 to R3, A, X and n are as defined herein, and an additional active agent. The present invention also relates to pharmaceutical compositions comprising these combinations, and methods of using these combinations to treat various diseases and disorders.Type: ApplicationFiled: March 5, 2013Publication date: September 12, 2013Applicant: Boehringer Ingelheim International GmbHInventor: Lars Anders BYLOCK
-
Publication number: 20130237580Abstract: The present invention relates to novel peptidomimetic compounds as therapeutic agents capable of inhibiting the programmed cell death 1 (PD1) signalling pathway. The invention also relates to derivatives of the therapeutic agents. The invention also encompasses the use of the said therapeutic agents and derivatives for treatment of disorders via immunopotentiation comprising inhibition of immunosuppressive signal induced due to PD-1, PD-L1, or PD-L2 and therapies using them.Type: ApplicationFiled: March 7, 2013Publication date: September 12, 2013Applicant: AURIGENE DISCOVERY TECHNOLOGIES LIMITEDInventors: POTTAYIL GOVINDAN NAIR SASIKUMAR, MURALIDHARA RAMACHANDRA, SEETHARAMAIAH SETTY SUDARSHAN NAREMADDEPALLI
-
Patent number: 8530462Abstract: The present invention relates to novel indole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: GrantFiled: November 10, 2011Date of Patent: September 10, 2013Assignee: Allergan, Inc.Inventors: Santosh C. Sinha, Smita S. Bhat, Ken Chow, Michael E. Garst, Wha Bin Im
-
Publication number: 20130230512Abstract: The present invention includes inhibitors of the amino acid transporter ATB0,+ and methods of uses thereof.Type: ApplicationFiled: March 11, 2013Publication date: September 5, 2013Applicant: Georgia Health Sciences University Research Institute, Inc.Inventor: Georgia Health Sciences University Research Institute, Inc.
-
Publication number: 20130231323Abstract: Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R1, R2, R3, R101, L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections.Type: ApplicationFiled: September 6, 2011Publication date: September 5, 2013Applicant: DUKE UNIVERSITYInventors: Pei Zhou, Eric J. Toone
-
Publication number: 20130230577Abstract: The present invention concerns the treatment of serotonergic dysregulation disorders and/or augmentation of serotonin levels in the brain by add-on treatments to serotonin enhancers, and slow-release formulations of 5-hydroxytryptophan (5-HTP) therefor.Type: ApplicationFiled: April 19, 2013Publication date: September 5, 2013Applicant: Duke UniversityInventors: Jacob P.R. Jacobsen, Marc G. Caron
-
Patent number: 8524917Abstract: The invention provides compounds represented by the formula I, each of which compounds may have sphingosine-1-phosphate receptor agonist and or antagonist biological activity: and wherein the variables Y, R4, n, o, A, A1, A2, X, Z, R1, R3, R2, p, q and r are as defined in the specification. These compounds are useful for treating a disease or condition selected from the group consisting of glaucoma, dry eye, angiogenesis, cardiovascular conditions and diseases, and wound healing.Type: GrantFiled: January 11, 2008Date of Patent: September 3, 2013Assignee: Allergan, Inc.Inventors: Richard L. Beard, Haiqing Yuan, John E. Donello, Xiaoxia Liu, Tien Duong
-
Publication number: 20130225617Abstract: Compounds of the invention are ligands of the CRTH2 receptor, useful inter alia for treatment of inflammatory conditions.Type: ApplicationFiled: January 31, 2013Publication date: August 29, 2013Applicant: PULMAGEN THERAPEUTICS (ASTHMA) LIMITEDInventor: PULMAGEN THERAPEUTICS (ASTHMA) LIMITED
-
Publication number: 20130224151Abstract: The present disclosure relates to methods of using fatty acid amide hydrolase (FAAH) inhibitors alone or in combination for the treatment or prevention of abdominal, visceral or pelvic pain. Also described herein are pharmaceutical compositions comprising a FAAH inhibitor, alone or in combination with an additional therapeutic agent for the treatment of abdominal, visceral or pelvic pain.Type: ApplicationFiled: March 31, 2011Publication date: August 29, 2013Applicants: UNITED STATES OF AMERICA, IRONWOOD PHARMACEUTICALS, INCInventors: James Philip Pearson, Mark G. Currie, Yvette Tache, Muriel Larauche
-
Publication number: 20130225531Abstract: A composition and method of treating Alzheimer's disease or a dementia of vascular origin are disclosed. The composition and method utilize an endothelin antagonist as the active agent to treat Alzheimer's disease or a dementia of vascular origin in mammals, including humans.Type: ApplicationFiled: December 19, 2012Publication date: August 29, 2013Applicant: THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventor: The Board Of Trustees Of The University of Illinois
-
Publication number: 20130216560Abstract: The present invention inter alia provides a method, and use thereof, of predicting severe CVD complications such as AMI or CVD death by detecting the lipid concentrations or lipid ratios of a biological sample and comparing it to a control and has identified specific lipid markers that are more specific and sensitive in predicting these CVD complications than currently utilized clinical markers. Also provided is an antibodies towards said lipids, and the use thereof for predicting, diagnosing, preventing and/or treating CVD complications. The invention additionally relates to kits comprising lipids and/or an antibody thereto, for use in the prediction and/or diagnosis of CVD complications.Type: ApplicationFiled: June 20, 2011Publication date: August 22, 2013Applicant: ZORA BIOSCIENCES OYInventors: Reijo Laaksonen, Kim Ekroos, Reini Hurme, Minna Jänis, Riikka Katainen, Kirill Tarasov
-
Publication number: 20130217702Abstract: The present invention relates to the indole derivatives of formula (I), wherein R1-R6 and X are defined in the claims and optical antipodes or racemates and/or salts thereof which are selective antagonists of bradykinin B1 to process for producing these compounds, pharmacological compositions containing them and to their use in therapy or prevention of painful and inflammatory conditions.Type: ApplicationFiled: November 4, 2011Publication date: August 22, 2013Inventors: Gyula Beke, Gyula Attila Bényei, István Borza, Éva Bozó, Sándor Farkas, Katalin Hornok, Andrea Papp, István Vágó, Mónika Vastag
-
Publication number: 20130209433Abstract: Methods for reducing peripheral blood glucose levels, food intake, glucose production, gluconeogenesis, triglyceride levels, and low density lipoprotein (VLDL) levels in mammals are provided. Also provided are methods of increasing glucose production and food intake in mammals. Further provided are methods of treating a disorder selected from the group consisting of obesity, type 2 diabetes, type 1 diabetes, hyperglycemia, insulin resistance, glucose intolerance, leptin resistance, metabolic syndrome, heart failure, ischemia, coronary heart disease, familial lipoprotein lipase deficiency, hypopituitarism, hyperlipidemia, hypertriglyceridemia, hyper-VLDLemia, atherosclerosis, hypercholesterolemia, hypertension, and any combination of the foregoing. The methods involve manipulations of amino acid presence or metabolism in the hypothalamus of the mammal.Type: ApplicationFiled: December 12, 2012Publication date: August 15, 2013Applicant: Albert Einstein College of Medicine of Yeshiva UniversityInventor: Albert Einstein College of Medicine of Yeshiva University
-
Publication number: 20130203830Abstract: The invention is related to compounds for prevention of cell injury or protection of cells. The compounds are involved in the maintenance or the increase of hydrogen sulphide in cells, which results in a protection of the cells or the prevention of cell injury. The compounds of the invention can be used in cell culture and tissue culture techniques. They can also be used in several medical conditions such as ischemia, reperfusion and hypothermia, or for preserving organs which are used for transplantation.Type: ApplicationFiled: April 18, 2011Publication date: August 8, 2013Applicant: SULFATEQ B.V.Inventors: Fatemeh Talaei, Robert Henk Henning, Adrianus C. Van der Graaf
-
Patent number: 8501800Abstract: An ophthalmically acceptable vehicle includes an aqueous suspension having a first viscosity. The suspension includes about 0.1% to about 6.5% by weight of a carboxyl-containing polymer prepared by polymerizing one or more carboxyl-containing monoethylenically unsaturated monomers and less than about 5% by weight of a cross-linking agent. The polymer has average particle size of not more than about 50 ?m in equivalent spherical diameter. The vehicle includes a second polymer that allows the carboxyl-containing polymer to remain suspended. Upon contact with tear fluid, the vehicle gels to a second viscosity which is greater than the first viscosity. A method of administering a medicament to the eye of a subject includes applying a composition that includes this ophthalmically acceptable vehicle and a medicament contained for treatment of a disease or disorder for which ophthalmic delivery is indicated. The medicament is released from the vehicle in a sustained release manner.Type: GrantFiled: March 5, 2009Date of Patent: August 6, 2013Assignee: Insite Vision IncorporatedInventors: Lyle Bowman, Stephen Pham
-
Patent number: 8501759Abstract: The present invention, which is applicable in the pharmaceutical industry, relates to the use of fibrates, in particular fenofibrate, especially in the form of a solid oral composition, for the manufacture of a drug for the treatment of sleep apnea, sleep apnea syndrome, in particular obstructive sleep apnea or obstructive sleep apnea syndrome.Type: GrantFiled: December 31, 2009Date of Patent: August 6, 2013Assignee: Fournier Laboratories Ireland LimitedInventor: Eric Bruckert
-
Publication number: 20130197046Abstract: The present application is directed to novel P2X7R antagonists that are indol-3-carboxamide or azaindole-3-carboxamide compounds, pharmaceutical compositions comprising the same and their use for the prophylactic or therapeutic treatment of diseases mediated by P2X7R activity.Type: ApplicationFiled: July 24, 2012Publication date: August 1, 2013Applicant: Affectis Pharmaceuticals AGInventor: Michael Bös
-
Publication number: 20130197053Abstract: Pharmaceutical compositions containing a compound of formula (I) wherein the radicals denote e.g.: R1 is hydrogen or C1-C8-alkyl; R2 is hydrogen or C1-C8-alkyl; R3 is hydrogen or C1-C8-alkyl; R4 is OH; R5 is hydrogen, and a pharmaceutically acceptable cyclodextrin derivative can be used for the preparation of ophthalmic formulations.Type: ApplicationFiled: July 6, 2011Publication date: August 1, 2013Applicant: MERZ PHARMA GMBH & CO. KGAAInventors: Bernard Hauptmeier, Kevin Kiehm, Patrick Plitt, Axel Tardt, Alda Szlak-Freier, Diana Strehl
-
Publication number: 20130195926Abstract: The instant invention provides methods for treating a solid tumor in a subject comprising modulating nitric oxide production in the tumor to normalize tumor vasculature and administering an anti-tumor therapy to the subject. The invention further provides methods of treating a solid tumor in a subject comprising selectively increasing cyclic guanosine monophosphate (cGMP) or cGMP dependent protein kinase G production in the tumor vasculature to an amount effective to normalize tumor vasculature and administering an anti-tumor therapy to the subject.Type: ApplicationFiled: December 4, 2012Publication date: August 1, 2013Applicant: The General Hospital CorporationInventor: The General Hospital Corporation
-
Publication number: 20130197026Abstract: The disclosure provides methods of treating glioblastoma, methods of screening for compounds that treat glioblastoma, and pharmaceutical compositions useful the treatment of glioblastoma.Type: ApplicationFiled: August 22, 2011Publication date: August 1, 2013Applicant: Unversity of Washington Through its Center for CommercializationInventors: Nephi Stella, Toni Kline
-
Publication number: 20130190321Abstract: Methods and kits for aiding in detection, assessment and treatment of a proliferative disorder of the prostate gland in a subject are provided according to aspects of the present invention which include assaying a first biological sample comprising prostate gland cells obtained from the subject for expression of one or more biomarkers selected from the group consisting of: alcohol dehydrogenase 1B, alcohol dehydrogenase 1C, alcohol dehydrogenase 4 and hepatocyte nuclear factor 1B; and determining, based on the expression of the one or more biomarkers in the sample that the subject has, or is at risk of having, a proliferative disorder of the prostate gland.Type: ApplicationFiled: January 23, 2013Publication date: July 25, 2013Applicant: WEST CHESTER UNIVERSITY OF PENNSYLVANIAInventor: West Chester University of Pennsylvania
-
Publication number: 20130184276Abstract: The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”), compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.Type: ApplicationFiled: October 16, 2012Publication date: July 18, 2013Applicant: VERTEX PHARMACEUTICALS INCORPORATEDInventor: Vertex Pharmaceuticals Incorporated
-
Patent number: 8486991Abstract: 3-phosphoindole compounds substantially in the form of a single enantiomer useful for the treatment of Flaviviridae virus infections, and particularly for HIV infections are provided. Also provided are pharmaceutical compositions comprising the 3-phosphoindole compounds alone or in combination with one or more other anti-viral agents, processes for their preparation, and methods of manufacturing a medicament incorporating these compounds.Type: GrantFiled: June 2, 2011Date of Patent: July 16, 2013Assignee: Idenix Pharmaceuticals, Inc.Inventors: Richard Storer, Francois-Rene Alexandre, Cyril Dousson, Adel M. Moussa, Edward Bridges, Alistair Stewart, Jing Yang Wang, Benjamin Alexander Mayes
-
Patent number: 8481587Abstract: The present invention relates to novel substituted 2-(5-hydroxy-2-methyl-1H-indol-3-yl)acetic acids, to novel antiviral active ingredients, pharmaceutical compositions, antiviral medicaments, methods for prophylaxis and treatment of viral diseases particularly caused by influenza viruses and infectious hepatisis C (HCV) viruses.Type: GrantFiled: November 27, 2009Date of Patent: July 9, 2013Inventors: Andrey Alexandrovich Ivashchenko, Nikolay Filippovich Savchuk, Alexander Vasilievich Ivashchenko, Pavel Mikhailovich Yamanushkin, Oleg Dmitrievich Mitkin, Vladimir Yurievich Vvedensky, Vadim Vasilievich Bichko
-
Patent number: 8481588Abstract: The present invention relates to crystalline forms of the mono-sodium salt of D-isoglutamyl-D-tryptophan, pharmaceutical compositions comprising them, their use in the treatment of various diseases and conditions, and processes for their preparation. In particular, the present invention relates the crystal modification 2 (polymorphic form I) of the mono-sodium salt of D-isoglutamyl-D-tryptophan.Type: GrantFiled: June 7, 2012Date of Patent: July 9, 2013Assignee: Apotex Technologies Inc.Inventors: Tim Fat Tam, Blaise N'Zemba, Regis Leung-Toung, Yingsheng Wang, Yanqing Zhao, Lily Yu
-
Publication number: 20130172390Abstract: The present invention relates to halogen-substituted amide derivatives of the general formula (I) in which R1 to R6, Q1 to Q8, A, V, W, X, Y, n and m are each defined as described in the description—and to a process for preparation thereof and to the use thereof as insecticides and acaricides.Type: ApplicationFiled: September 14, 2012Publication date: July 4, 2013Applicant: Bayer Intellectual Property GmbHInventors: Markus Heil, Eike Kevin Heilmann, Alexander Sudau, Tobias Kapferer, Friedrich August Mühlthau, Peter Jeschke, Arnd Voerste, Ulrich Görgens, Klaus Raming, Ulrich Ebbinghaus-Kintscher, Mark Drewes, Martin Adamczewski, Angela Becker
-
Publication number: 20130172397Abstract: The invention relates to the use of a compound of general formula (I), wherein R1 and R2 are independently H or C1-C6 alkyl, or R1 and R2 are bound to one another forming an optionally substituted fused benzene ring, R3 is H, C1-C6 alkyl or —CH2—CH(NH2)—COOH and R4 is H, C1-C6 alkyl, or R4 represents (II) or (III) in the preparation of a medicinal product for treating and/or preventing congenital erythropoietic porphyria (CEP).Type: ApplicationFiled: August 5, 2011Publication date: July 4, 2013Applicant: CENTRO DE INVESTIGACIÓN COOPERATIVA EN BIOCIENCIAS-CIC bioGUNEInventors: Oscar Millet Aguilar-Galindo, Ana Laín Torre
-
Publication number: 20130165398Abstract: A concentration-enhancing drink contains, in each case independently of one another, per liter: 1 mg to 10 g, preferably 1 to 1000 mg, still more preferably 10 to 500 mg, in particular 50 to 300 mg, of epigallocatechin gallate; 1 to 500 mg, preferably 10 to 100 mg, in particular 20 to 80 mg, of nicotinamide ribose; and/or 0.05 to 10 g, preferably 0.1 to 5 g, in particular 0.5 to 3 g of tryptophan.Type: ApplicationFiled: March 29, 2011Publication date: June 27, 2013Inventor: Johannes Huber
-
Patent number: 8470870Abstract: Solid forms comprising a compound useful in the treatment, prevention and management of various conditions and diseases are provided herein. In particular, provided herein are solid forms comprising (2-carbamoyl-5-chloro-1H-indol-3-yl)-[3-((E)-2-cyano-vinyl)-5-methyl-phenyl]-(R)-phosphinic acid methyl ester, including salts thereof, having utility for the treatment, prevention and management of conditions and disorders including, but not limited to, human immunodeficiency virus infection.Type: GrantFiled: March 27, 2009Date of Patent: June 25, 2013Assignee: Idenix Pharmaceuticals, Inc.Inventors: Adel M. Moussa, Mike H. O'Neill, Xiaohong Sheng
-
Patent number: 8470869Abstract: The present invention relates to new salts of perindopril, particularly to a new calcium salt and new amine salts of perindopril, to a process for their preparation and to a pharmaceutical formulations containing the new salts.Type: GrantFiled: June 27, 2008Date of Patent: June 25, 2013Assignee: KRKA, Tovarna Zdravil D.D. Novo MestoInventors: Marjo Merslavic, Sergeja Bombek, Urska Gojak, Matej Smrkolj, Rok Zupet
-
Publication number: 20130158093Abstract: The present invention is related to a method of determining a test compound's ability to modify the biological activity of a GPR17. Said method comprises, among others, the step of contacting the test compound with a GPR17, or a functional GPR17 fragment in the presence of a suitable amount of a GPR17 agonist of formula I.Type: ApplicationFiled: February 25, 2013Publication date: June 20, 2013Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONNInventor: Rheinische Friedrich-Wilhelms-Universität Bonn
-
Publication number: 20130158021Abstract: Described herein are compounds and compositions characterized, in certain embodiments, by conjugation of various groups, such as lipophilic groups, to an amino or amide group of an amino acid, a linear or cyclic peptide, a linear or cyclic polypeptide, or structural isomer thereof, to provide compounds of the present invention, collectively referred to herein as “APPLs”. Such APPLs are deemed useful for a variety of applications, such as, for example, improved nucleotide delivery. Exemplary APPLs include, but are not limited to, compounds of Formula (I), (II), (III), (IV), (V), and (VI), and salts thereof, as described herein: wherein m, n, p, R?, R1, R2, R3, R4, R5, R8, Z, W, Y, and Z are as defined herein.Type: ApplicationFiled: October 26, 2012Publication date: June 20, 2013Applicant: Massachusetts Institute of TechnologyInventor: Massachusetts Institute of Technology
-
Publication number: 20130158035Abstract: Screening methods for identifying compounds and compounds and pharmaceutical compositions for treating and preventing cancer are disclosed. The compounds affect signal transduction downstream of the MET receptor.Type: ApplicationFiled: August 23, 2011Publication date: June 20, 2013Applicant: Brigham Young UniversityInventor: Marc Hansen
-
Publication number: 20130158070Abstract: Novel chemical conjugates derived from unsaturated fatty acids and therapeutically active agents, are disclosed. The chemical conjugates are designed and characterized as COX-2 and/or 5-LOX inhibitors and are useful in the treatment of inflammatory diseases and disorders such as Alzheimer's disease, Parkinson's disease, asthma, osteoarthritis, rheumatoid arthritis, pain, primary dysmenorrhea, Crohn's disease and ulcerative colitis.Type: ApplicationFiled: September 6, 2011Publication date: June 20, 2013Inventor: Taher Nassar
-
Publication number: 20130150346Abstract: The present disclosure relates to methods of using fatty acid amide hydrolase (FAAH) inhibitors to treat aspects of Parkinson's disease (PD), restless legs syndrome (RLS) and periodic limb movement disorder (PLMD), the use of FAAH inhibitors for the manufacture of medicaments for use in the treatment of PD, RLS and PLMD, as well as pharmaceutically acceptable compositions comprising FAAH inhibitors for use in the treatment of PD, RLS and PLMD.Type: ApplicationFiled: January 7, 2011Publication date: June 13, 2013Applicants: Ironwood Pharmaceutical, Inc.Inventors: James Philip Pearson, Todd G. Milne, Thomas Henry Johnston, Jonathan Michael Brotchie
-
Publication number: 20130150393Abstract: A composition for increasing the bioavailability of a statin active pharmaceutical ingredient (“API”) in humans and animals, wherein that composition includes a statin API selected from the group consisting of atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin, a first water soluble surfactant having a cloud point greater than about 37° C., a second water soluble surfactant having a cloud point greater than about 37° C., wherein a mixture of the first surfactant and the second surfactant comprises a cloud point less than about 37° C.Type: ApplicationFiled: December 12, 2012Publication date: June 13, 2013Applicant: PRUGEN IP HOLDINGS, INC.Inventor: Prugen IP Holdings, Inc.
-
Publication number: 20130142815Abstract: The present invention demonstrates for the first time that alpha-methyl-tryptophan is an inhibitor of the enzyme indoleamine diooxygenase (IDO). The present invention includes the use of alpha-methyl-tryptophan in methods of modulating immune responses and treating cancer and infections.Type: ApplicationFiled: February 9, 2011Publication date: June 6, 2013Applicant: Georiga Health Sciences Univ. Research Inst., Inc.Inventor: Vadivel Ganapathy